Emerging nanotaxanes for cancer therapy. (May 2021)

• Record Type: Journal Article
• Authors: Zhang, Yachao; Zhang, Wenjing; Wang, Yongqi; Zhu, Jiaojiao; Zhou, Mei; Peng, Can; He, Zhonggui; Sun, Jin; Li, Zhenbao; Gui, Shuangying
• Is Part Of: Biomaterials. Volume 272(2021)
• Publication Date: 2021-05
• Subjects: Nanotaxane -- Targeted delivery -- Stimuli-responsive -- Resistance and metastasis -- Synergistic therapy; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2021.120790
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: The clinical application of taxane (including paclitaxel, docetaxel, and cabazitaxel)-based formulations is significantly impeded by their off-target distribution, unsatisfactory release, and acquired resistance/metastasis. Recent decades have witnessed a dramatic progress in the development of high-efficiency, low-toxicity nanotaxanes via the use of novel biomaterials and nanoparticulate drug delivery systems (nano-DDSs). Thus, in this review, the achievements of nanotaxanes—targeted delivery and stimuli-responsive nano-DDSs—in preclinical or clinical trials have been outlined. Then, emerging nanotherapeutics against tumor resistance and metastasis have been overviewed, with a particular emphasis on synergistic therapy strategies (e.g., combination with surgery, chemotherapy, radiotherapy, biotherapy, immunotherapy, gas therapy, phototherapy, and multitherapy). Finally, the latest oral nanotaxanes have been briefly discussed. Graphical abstract: S chematic illustration on targeted delivery, stimuli-responsive drug release, drug resistance, metastasis, combinational therapeutics, and oral delivery of nanotaxanes for cancer therapy. Image 1 Highlights: We first outline the achievements of nanotaxanes in clinical studies—targeted delivery and stimuli-responsive nano-DDSs. Emerging nanotherapeutics against tumor resistance and metastasis have been overviewed, with a particular emphasis on synergistic therapy strategies. The latest oral nanotaxanes have been briefly discussed.